
Eza sold off $ 2.40 long ago bought at 1.80...but now U hve free triyards free recently so I guess U shd break even..Ezra very slow moving not much institutional interest Ezrion better but too high liao..Auric I only collect at < 1.05..sold off the bulk 1.37-1.39...STXOSV if dropped below 1.5 will collect more..Ascendas HT just went in today..50lots 1.26cts per lot still hve some pocket $$$
cheerstan2002 ( Date: 07-Nov-2012 13:00) Posted:
|
Dear starlene, btw, I discover u & I got the same counter too. I got Ascendas and Biosensors. But I got Ezra got in at 1.15, not so great ( actually rather disappointing counter at this moment). It keeps on falling can't cross 1.185, recently rally, didn't let go and then fall so quickly till present support, which I think is 1.05 - 1.07.
Giove me your opinion about Ezra .... Cheers
Also watching Auric and STX, but no money liao ...

Hope to hear form you.
 
starlene ( Date: 07-Nov-2012 10:47) Posted:
|
Bought 50 lots of Ascendas Hospitality Trust at 92cts for 3-6mths since most good trust like the Maple tree group,Ascendas,Sabanas,Ascott Reit..likley will cross $1...a matter of time
starlene ( Date: 07-Nov-2012 10:08) Posted:
|
many shorted   Bios all the way from $1.20 to $1.05....so if results turn out to be excellent..the spurt up will be magnified as U see curried short covering
hmmmm....  if my eyes ain't playing tricks on me.... Goldman Sachs sighted picking up Biosensors from retailers...
osensors International Group
OCBC on 2 Nov 2012
We lower our FY13/14F revenue forecasts on Biosensors International Group (BIG) by 2.7/4.0%, and our core PATMI projections by 3.7/4.3% as we expect weaker licensing revenues and softer sales growth from Europe. Nevertheless, we believe that BIG remains well-positioned to capture market share from its competitors given continued positive clinical trial data for its flagship BioMatrix™ family of drug-eluting stents. BIG’s recent share price pullback appears to be overdone, in our view. Despite our earnings cut and a lower adopted USD-SGD assumption, we opine that valuations for BIG are still compelling. The stock trades at 11.3x blended FY13/14F core EPS, which is approximately 1.5 SD below its 3-year average forward core PER. Maintain BUY, with a revised fair value estimate of S$1.70, from S$1.81 previously.
Licensing revenues could be weaker-than-expected
During Terumo Corp’s (Terumo) recent 2QFY13 results, a disappointing note came from the sluggish sales performance from its Nobori® drug-eluting stent (DES) in Japan. We expect this to translate into weaker licensing revenues for Biosensors International Group’s (BIG) upcoming 2QFY13 results (7 Nov after market close). As a recap, Terumo licenses BIG’s DES technology in exchange for a royalty fee. The revenue slowdown in Nobori® in Japan can be attributed to market share loss due to the launch of new products by three competitors (including Abbott Lab’s XIENCE PRIME™ DES) and a downward revision of the National Health Insurance’s reimbursement prices (~15%). Nevertheless, one of Terumo’s key initiatives in 2HFY13 is to regain its Nobori® market share in Japan by re-accentuating its competitive advantages such as its proven long-term safety and efficacy track record and superiority in the treatment of particular lesions. Meanwhile, there could also be some softness in BIG’s sales from Europe, given the weak macroeconomic environment, although we believe that BIG remains well-positioned to capture market share from its competitors. We pare our FY13/14F revenue forecasts by 2.7/4.0%, and our core PATMI projections by 3.7/4.3%. We also lower the USD-SGD assumption in our model (US$1 = SG$1.22, previously S$1.28).
Clinical trial data continues to be positive
BIG recently announced five-year results from the LEADERS trial at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) symposium, an important interventional cardiology event. Long-term clinical outcomes for its flagship BioMatrix Flex™ stent system were favourable. We expect this to drive BIG’s continued market share penetration moving forward.
Share price weakness creates buying opportunities
We opine that BIG’s recent share price pullback has been overdone. Despite our earnings cut and lower USD-SGD assumption, valuations for BIG still appear compelling, in our view. The stock trades at 11.3x blended FY13/14F core EPS, which is approximately 1.5 SD below its 3-year average forward core PER. Maintain BUY, with a revised fair value estimate of S$1.70, from S$1.81 previously.
OCBC on 2 Nov 2012
We lower our FY13/14F revenue forecasts on Biosensors International Group (BIG) by 2.7/4.0%, and our core PATMI projections by 3.7/4.3% as we expect weaker licensing revenues and softer sales growth from Europe. Nevertheless, we believe that BIG remains well-positioned to capture market share from its competitors given continued positive clinical trial data for its flagship BioMatrix™ family of drug-eluting stents. BIG’s recent share price pullback appears to be overdone, in our view. Despite our earnings cut and a lower adopted USD-SGD assumption, we opine that valuations for BIG are still compelling. The stock trades at 11.3x blended FY13/14F core EPS, which is approximately 1.5 SD below its 3-year average forward core PER. Maintain BUY, with a revised fair value estimate of S$1.70, from S$1.81 previously.
Licensing revenues could be weaker-than-expected
During Terumo Corp’s (Terumo) recent 2QFY13 results, a disappointing note came from the sluggish sales performance from its Nobori® drug-eluting stent (DES) in Japan. We expect this to translate into weaker licensing revenues for Biosensors International Group’s (BIG) upcoming 2QFY13 results (7 Nov after market close). As a recap, Terumo licenses BIG’s DES technology in exchange for a royalty fee. The revenue slowdown in Nobori® in Japan can be attributed to market share loss due to the launch of new products by three competitors (including Abbott Lab’s XIENCE PRIME™ DES) and a downward revision of the National Health Insurance’s reimbursement prices (~15%). Nevertheless, one of Terumo’s key initiatives in 2HFY13 is to regain its Nobori® market share in Japan by re-accentuating its competitive advantages such as its proven long-term safety and efficacy track record and superiority in the treatment of particular lesions. Meanwhile, there could also be some softness in BIG’s sales from Europe, given the weak macroeconomic environment, although we believe that BIG remains well-positioned to capture market share from its competitors. We pare our FY13/14F revenue forecasts by 2.7/4.0%, and our core PATMI projections by 3.7/4.3%. We also lower the USD-SGD assumption in our model (US$1 = SG$1.22, previously S$1.28).
Clinical trial data continues to be positive
BIG recently announced five-year results from the LEADERS trial at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) symposium, an important interventional cardiology event. Long-term clinical outcomes for its flagship BioMatrix Flex™ stent system were favourable. We expect this to drive BIG’s continued market share penetration moving forward.
Share price weakness creates buying opportunities
We opine that BIG’s recent share price pullback has been overdone. Despite our earnings cut and lower USD-SGD assumption, valuations for BIG still appear compelling, in our view. The stock trades at 11.3x blended FY13/14F core EPS, which is approximately 1.5 SD below its 3-year average forward core PER. Maintain BUY, with a revised fair value estimate of S$1.70, from S$1.81 previously.
Above all, don't forget to pray to Kwan Yin otherwise, all bets are off. 

investorteng ( Date: 06-Nov-2012 09:56) Posted:
|
Ok thank you bro. Good luck to you too
solomonster ( Date: 06-Nov-2012 09:44) Posted:
|
4) Buy only when below NAV 
-sometimes stock price always > NAV. will you consider it?
5) Sell when downtrend comfirm,let yr profits run otherwise sell too early....all sound too familiar..but main thing play only with $$$ U can afford to lose..be prepared to lose in the worst scenario b4 U think of making profits
confirmation  based ob fundamental data or technical respond? usually FA will have faster reaction to price. is MACD 20-50 a strong measurement tools?
thank you for clear explaination. 
starlene ( Date: 05-Nov-2012 15:12) Posted:
|
might join you tomorrow if my setup is hit. This baby is getting weaker.
I am rather conservative....anyway, good luck!
chartreader ( Date: 06-Nov-2012 09:31) Posted:
|
I don't think Biosensor will go to 50cts again...during Lehman bros fiasco ever hit 25-29cts...that was the past ..with JW Medical System as its subsidiary and opening of new mkts and closing down of unprofitable/cutting admin costs Biosensor is the new creation-unlikley to drop to 50cts again..last placement was $0.9283 in March....results shd be in line with analysts'expectations on the upward bias...hope some reward maybe dividends for the first time or bonus issue(surprise)
tiptop123 ( Date: 02-Nov-2012 20:09) Posted:
|
No offense. Sending some short scout yesterday 1.13 and main troops today 1.15
Auric < $1.10 (NAV $1.68) and STXOSV (< 1.500 should collect)..
 
1)  Buy 150MA above 50MA...ie buy only on uptrend,as a cheap stock can become even cheaper
2) Never buy on rumours
3) Technical & fundamental analysis
4) Buy only when below NAV
5) Sell when downtrend comfirm,let yr profits run otherwise sell too early....all sound too familiar..but main thing play only with $$$ U can afford to lose..be prepared to lose in the worst scenario b4 U think of making profits
cheerstan2002 ( Date: 05-Nov-2012 12:42) Posted:
|
I would to ask also how do find counters that have limited downside and yet able to rise?
At this present moment, which counter has limited downside and has potential to rise?
investorteng ( Date: 05-Nov-2012 10:53) Posted:
|
hi there, very impress with your result. but i have an enquiries which is how can you hold the share until the let go price, any method to convince yours still keep the share even already have 100% return. 
starlene ( Date: 05-Nov-2012 10:01) Posted:
|
Play share only when hve spare cash ...just like I bought Fragrance (1 for 1 bonus) and Aspial also a few hundred lots and I know limited downside....anyway normally if> 6cts drop I cut...disciplined...now I own Auric Pacific( bought 72cts all the way to 92cts)..STX OSV from (80cts to $1.25-made many rounds and get all their dividends liao)..Biosensor is also my favourite...since I hve bought previously at 60cs b4..now 1.13-1.135..shd be quite safe but limited upside $1.35 the most but am prepared to make $40,000 over this short term
cheerstan2002 ( Date: 03-Nov-2012 13:00) Posted:
|
Wow, sound good, starlene! u got gd judgment. your entry pt is good. I got in at 1.2. I need patience for Biosenors to rise above 1.2.
  BTW, what other counter are u eyeing at now.....if u can share.... and maybe can tell us what is a good entry point too...
Cheers
yiming2000 ( Date: 02-Nov-2012 23:07) Posted:
|
Wah 400 lots at $1.07! that is $428,000. Friend Starlene, are you a BB? It is now 1.12. Your stock is now worth $448,000. You made $20,000.
If you ride this up to $1.50 where I get off, your stock will be worth $600,000 and you will make $172,000! 

starlene ( Date: 02-Nov-2012 16:44) Posted:
|
You sounded more like the author trying to promote your own blog.
Where got people so free to create a new account just to post this!
Head and shoulders pattern has less than 40% chance of breakout. 
 
championz ( Date: 01-Nov-2012 14:06) Posted:
|
I love Biosensor..even bought a few hundred lots at 60cts and sold off $1.30-1.37 b4 seeing it went to $1.60..always go for your winning stocks
In march this year there was a successful private placement of 216.3new shares at about 0.92 and in Sept Co has been given approval from SGX on the issuance of consideration & conversion shares for the acquisition of the remaining 50% in JW Medical Systems